Hormonal
Chronic nutrient excess and obesity overwhelm adipose tissue storage capacity, causing ectopic lipid accumulation in liver and muscle, which triggers lipotoxicity and metaflammation, leading to insulin resistance and metabolic disease.
When you consistently consume more energy than your body can store in fat tissue, the excess fat spills over into organs like the liver and muscles. This spillage is toxic and triggers inflammation that blocks insulin, leading to type 2 diabetes. Managing nutrient intake to stay within your body's storage capacity is key to preventing this cascade.
When metabolic stress becomes chronic and adaptive mechanisms are overwhelmed, as occurs during prolonged nutrient excess or obesity, lipid influx can exceed the adipose tissue storage capacity and result in accumulation of harmful lipid species at ectopic sites such as liver and muscle.
Why this rating
Based on a comprehensive review of multiple mechanistic studies and mouse models.
Source
Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment
Meric Erikci Ertunc et al. · Journal of Lipid Research · 2016
DOI 10.1194/jlr.r066514
More from this paper
- Saturated fatty acids (e.g., palmitate) and oxidized cholesterol drive metaflammation by activating stress kinases (JNK, PKC, PKR) and inflammatory pathways (TLR4, NF-kB), which directly inhibit insulin signaling.Good
- Inhibition of ceramide synthesis improves glucose and energy metabolism by recovering insulin signaling in liver and muscle.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →